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Introduction
Organic anion-transporting polypeptides (OATP/Oatp; SLCO/Slco) are sodiumindependent uptake transporters that mediate the cellular uptake of a broad range of substrates (Hagenbuch and Meier, 2004) . OATP1A/1B transporters are highly expressed in organs such as liver, kidney and small intestine in both human and mice (Cheng et al., 2005; Konig et al., 2000a;  b; Lee et al., 2005) . OATP1A2 (SLCO1A2) is currently thought to be expressed on the apical membranes of intestinal enterocytes, distal nephrons in the kidney, cholangiocytes lining the bile ducts in the liver, and capillary endothelial cells at the blood-brain barrier (Gao et al., 2000; Glaeser et al., 2007; Lee et al., 2005) , and thereby mediates the oral bioavailability, renal secretion and CNS distribution of drug substrates. OATP1B1 and OATP1B3 (SLCO1B1 and SLCO1B3) are predominantly expressed at the basolateral membranes of hepatocytes in the liver, and have been implicated to play key roles in the hepatic uptake and plasma clearance of a number of drug substrates and toxins (Hagenbuch and Gui, 2008; Konig et al., 2000a; . Of note, OATP1A/1B transporters have been found to be expressed in a number of cancer tissues, including breast, gastrointestinal, colon, ovarian, pancreatic, lung, prostate, and bone cancers, and cancer cell lines such as breast, prostate, and ovarian cancer cell lines (Abe et al., 2001; Arakawa et al., 2012; Ballestero et al., 2006; Liedauer et al., 2009; Miki et al., 2006; Svoboda et al., 2011) . Although not extensively investigated to date, the expression of OATP1A/1B transporters in cancer tissues may facilitate tumor uptake of endogenous compounds that drive proliferation and growth. Alternatively, OATPs may be considered as important therapeutic targets in anti-cancer drug design due to their high transport activity for many cancer drugs and their overexpression in certain cancers may facilitate tumor accumulation of such drugs (Thakkar et al., 2015) .
Historically, the typical substrates of OATPs, including OATP1A/1B transporters, were believed to be mainly polar and anionic drugs (Hagenbuch and Meier, 2003; . Interestingly, however, they have been found to transport a large number of structurally divergent compounds (Kullak-Ublick et al., 1995; Kullak-Ublick et al., 2001) , including many drugs in clinical use, such as methotrexate (anion), paclitaxel (bulky hydrophobic) and fexofenadine (zwitterion) (van de Steeg et al., 2011; van de Steeg et al., 2010) . The anthracycline doxorubicin is a chemotherapeutic agent that is used in the treatment of a wide range of cancers, including nonHodgkin's and Hodgkin's lymphoma, multiple myeloma, lung, ovarian, gastric, thyroid, breast, sarcoma, and pediatric cancers (Cortes-Funes and Coronado, 2007; Weiss, 1992) . The major mechanisms by which doxorubicin exerts its pharmacologic effects involve intercalation into DNA, leading to inhibition of the DNA synthesis or poisoning of topoisomerase II (TOP2A) and generation of free radicals, leading to DNA and cell membrane damage (Gewirtz, 1999) . Since doxorubicin is a hydrophobic weak base and cation at physiological pH, it had not been considered a potential substrate for OATP transporters. Recently, however, Durmus et al. demonstrated that OATP1A/1B transporters play a substantial role in the in vivo disposition of doxorubicin (Durmus et al., 2014) . However, while doxorubicin is widely known to be a substrate for ABC-family drug efflux transporters such as P-glycoprotein (P-gp; MDR1), MRP2
and BCRP (Allen et al., 1999; van Asperen et al., 2000; Vlaming et al., 2006) , significantly less is known regarding its interactions with drug uptake transporters that could mediate its cellular uptake and clearance.
In this study, we aimed to define the relevant role of OATP transporters to the disposition of doxorubicin through in vitro model cell systems in HeLa and MDCKII cell lines and in vivo using an Oatp1a/1b knockout mouse model. We identified OATP1A2, OATP1B1 attained using a mouse model. Our data support significant roles for OATP transporters in the hepatic uptake, clearance, and plasma exposure of doxorubicin.
Materials and Methods

Chemicals and reagents
Radiolabeled [
3 H]doxorubicin (1.2 Ci/mmol; >98% purity) was obtained from Moravek Biochemicals (Brea, CA). Unlabeled doxorubicin (>97% purity) was obtained from SigmaAldrich. All other chemicals and reagents, unless stated otherwise, were obtained from SigmaAldrich research and were of the highest grade available.
Cell culture and virus preparation
HeLa cells, purchased from the ATCC (July 2012), were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen). The polarized Madin-Darby Canine Kidney II (MDCKII) cells were purchased from Sigma-Aldrich (January 2013). The transporter-expressing and vector-transfected MDCKII cells were grown in DMEM containing high glucose and Lglutamine (Invitrogen) supplemented with 10% heat inactivated FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen). All cells used in this study were maintained in a 5% CO2
atmosphere at 37°C in a humidified incubator.
Preparation of viral stock of vtf-7 virus was prepared as described previously (Ho et al., 2004) . Briefly, HeLa cells grown to near confluence in 25-cm tissue culture plates were infected with 1 plaque-forming unit (PFU)/10 cells. After an incubation period of 48 h at 37°C, the infected cells were pelleted, homogenized, and recovered through centrifugation, followed by tittering of viral stock as described by Blakely and colleagues (Blakely et al., 1991) .
Generation of Wild-type and Variant OATP1A2 Expression Plasmids
Generation of pEF6/V5-His/OATP1A2 wild-type (SLCO1A2*1), a plasmid containing the full open reading frame (ORF) of human SLCO1A2 cDNA in the pEF6/V5-His-TOPO® vector (Invitrogen) was described previously (Lee et al., 2005) . In addition, the pEF6/V5-His/Oatp1a1 and -Oatp1a4 plasmids containing rat uptake transporters and the identified six nonsynonymous allelic variants of SLCO1A2 (T38C (rs10841795, I13T, *2), A516C
(rs11568563, E172D, *3), G559A (rs11045959, A187T, *4), A382T (rs11568567, N128Y, *5), A404T (rs45502302, N135I, *6), and C2003G (rs11568557, T668S, *7)) packaged into pEF6/V5-His-TOPO® vector were also created previously (Lee et al., 2005) . In brief, OATP1A2 variant plasmids were generated by Site-directed mutagenesis using the QuikChange® sitedirected mutagenesis kit (Stratagene, La Jolla, CA) by using OATP1A2 cDNA sequences in pEF6/V5-His/OATP1A2 (WT) plasmid as a template. All plasmids were constructed without the stop codon to generate epitope-tagged proteins including V5 when ligated into the pEF6/V5-His-TOPO® vector.
To generate pcDNA3.1(+)/OATP1A2-V5 (WT) plasmid, the full ORF of SLCO1A2 cDNA was amplified by PCR using pEF6/V5-His®/OATP1A2 plasmid as the template and then ligated into the pcDNA3.1(+) vector (Invitrogen were generated and characterized previously . For this study, single-(MDCKII-OATP1A2) and double-(MDCKII-OATP1A2/MDR1) transfected cells were also generated using the same methods as conducted previously . Briefly, both parent MDCKII cells and MDCKII-MDR1 cells were transfected or retransfected with the plasmids pcDNA3.1(+)/OATP1A2 using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Between 32-48 hr after transfection, the cells were split and divided into 10-cm culture dishes with fresh media containing G-418 sulfate (800 µg/mL; Mediatech).
After additional selection with G-418 sulfate, screening for single colonies of transfectants was conducted by immunoblot analysis using anti-V5 antibody (Invitrogen) to identify cell clones with the OATP1A2 protein expression. All expression values were normalized to the protein β -actin. Consequently, cell clones with the highest protein expression comparable with the expression of the control cell lines were chosen and used for the following transport studies.
Crude cell membrane fractions and immunoblot analysis
Protein expressions from MDCKII-OATP1A2 and -OATP1A2/MDR1 cells, including control cells were examined by immunoblot analysis of plasma membrane enriched preparations.
Crude cell membrane fractions were conducted as described previously with minor modification (Kim et al., 1998; Lee et al., 2015) . Briefly, cells were scraped, collected, and homogenized in 5 mM Hepes (pH 7.2) cell lysis buffer containing 1x protease inhibitor cocktails (Roche used as a marker of cell membrane proteins. Finally, the protein bands on the blots were detected using the Western lightning plus enhanced chemiluminescence ECL (PerkinElmer).
Immunofluorescence Confocal Microscopy
To confirm the membrane localization of OATP1A2 and MDR1 in MDCKII-MDR1 cells 
Transport assays
Recombinant vaccinia-based uptake transport assay.
Doxorubicin transport assays using a recombinant vaccinia-based method for recombinant transporter expression were conducted as described previously (Lee et al., 2005) . hours. The parental plasmid lacking any insert was used as control. Uptake (radioactivity) of doxorubicin was measured after an incubation of 10 minutes. Total radioactivity was determined after the addition of cell lysates to vials containing 5 mL of Biodegradable Scintillation Cocktail (Amersham Biosciences). Retained cellular radioactivity was quantified by liquid scintillation counter (PerkinElmer). Transport activities were expressed in the percentage compared with the vector control. All experiments were carried out in duplicate on at least 2 to 3 experimental days.
In each set of experiments, taurocholate uptake into cells transfected to express sodium/taurocholate cotransporting polypeptide (NTCP) was included as a positive control for transfection and expression efficiency. In each set of experiments, doxorubicin uptake into the cells transfected with the vector only was included as a negative control to ensure that results
were not confounded by an effect of the transfection process.
Transwell-based vectorial transport assay.
Vectorial transport assays of doxorubicin were conducted as described previously . MDCKII cells were seeded onto 12-Transwell (diameter 12 mm; pore size 0.4 mm;
Corning Incorporated) at an initial density of 0.4 x 10 6 cells per well and grown for total 4 days.
At 24 hours before the transport study is conducted the cell culture medium was replaced with culture medium supplemented with 10 mM sodium butyrate to induce transporter expression (Chen et al., 1997) . After washing cells with prewarmed uptake buffer Opti-MEM 1 medium (reduced serum, Invitrogen), 0.8 mL of uptake buffer was added to the basal (for OATP1A2 cells)
and apical (for OATP1B cells) compartments of the cell monolayers, respectively. Sequentially, the same amount of uptake buffer containing 1.0 µM and 0.2 µM of radiolabeled doxorubicin was added to the opposite sides, the apical and basal compartments, of the OATP1A2-and OATP1B-expressing cell monolayers, respectively. Consequently, as a control, the experiments were repeated in the opposite directions as well. Cells were then incubated at 37°C for given time points, 0.5, 1, 2 and 3 hours. At each time point, aliquots (50 µL) were taken from both the apical and basal compartments. The aliquots obtained from given time points were added to vials containing 5 mL of Biodegradable Scintillation Cocktail (Amersham Biosciences) and the radioactivity of doxorubicin was then measured by liquid scintillation counter (PerkinElmer).
After taking final media post-3 hr incubation, the incubation buffer was removed and uptake was terminated by adding ice-cold PBS buffer and washed twice with PBS buffer. Cells were then lysed with 0.2% SDS solution containing 1x protease inhibitor cocktail (Roche), followed by protein assay with BCA Assay Kit (Thermo Fisher Scientific). Meanwhile, to measure intracellular doxorubicin, cells in transwells were incubated as described above and the proper plates at designated time points were removed from the incubator. Cells were then washed, lysed, followed by determining doxorubicin radioactivity and protein concentration. All experiments were performed a minimum of three times in tetraplicates. 
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OATP1A2 variants differentially transport doxorubicin in vitro
To examine the effect on doxorubicin transport mediated by OATP1A2 polymorphisms, a panel of six known OATP1A2 nonsynonymous variants in addition to wild-type OATP1A2 (*1) was expressed in HeLa cells and evaluated for differential transport of doxorubicin in vitro.
Several variants, including 38T>C, 404A>T, 516A>C, and 559G>A, were associated with significantly impaired doxorubicin uptake when compared to the WT reference allele, SLCO1A2*1. In contrast, the other two variants, 382A>T and 2003C>G, exhibited no significant difference compared to the WT reference control (1*) (Fig. 3) .
Membrane localization of OATP1A2 in OATP1A2-and OATP1A2/MDR1-transfected
MDCKII cells
The transcriptional or protein expression of constitutive OATP1A2 as well as hepatic
OATP1Bs is absent in MDCKII cells (Goh et al., 2002; Konig et al., 2000a; . Hence, we used a MDCKII model cell system to examine the directional drug transport activity mediated by OATP transporters. We generated MDCKII cell lines stably expressing an uptake transporter OATP1A2.
The protein expression of OATP1A2 and MDR1 was characterized in OATP1A2-expressing MDCKII-WT and MDCKII-MDR1 cells. The expression of OATP1A2 and MDR1 in single or double transfectants was confirmed by immunoblot analysis (Fig. 4A ). OATP1A2 was detected as a single protein band with an unglycosylated form MW ~58 kDa (Lee et al., 2005) in OATP1A2-transfected all cells. We were also able to detect human MDR1 with the predicted molecular mass of ~ 170 kDa as described previously , whereas any proteins of interest were not detectable in control cells (MDCKII-Co). The plasma membrane protein marker, Na 
Slco1a/1b -/-mice significantly alter the hepatic disposition of doxorubicin
To further evaluate the relevance of OATP1A/1B transporters to doxorubicin disposition, we sequentially examined the in vivo effect of Oatp1a/1b deficiency in mice on doxorubicin disposition up to 120 min after I.V. administration of radiolabeled doxorubicin. Male Slco1a/1b -/-mice and male WT littermate controls were used for doxorubicin distribution experiments.
Plasma doxorubicin was significantly increased in the Oatp1a/1b -/-mice compared to the WT mice up to 60 min (Fig. 7A ), leading to a 2.0-fold higher plasma concentration (133.52 versus 260.72 ng/mL, p < 0.05). At early time points 5, 15 and 30 min after administration, plasma doxorubicin levels were significantly increased by 1.6-(p < 0.01), 1.9-(p < 0.01) and 1.6-fold (p < 0.01) in Oatp1a/1b -/-mice compared to WT. The total plasma AUC in Slco1a/1b -/-mice was approximately 1.7-fold greater than in WT mice (mean doxorubicin plasma AUC ± SD: WT, 18399 ± 587.9 ng·min/mL; Oatp1a/1b -/-, 31779 ± 5006 ng·min/mL, P < 0.01). Whereas plasma doxorubicin AUC was significantly higher in Slco1a/1b -/-versus wild-type mice, liver doxorubicin concentrations in Slco1a/1b -/-mice were significantly decreased compared to WT mice (p < 0.01) (Fig. 7B) . Accordingly, the liver-to-plasma ratio of doxorubicin was 2.3-fold lower in Slco1a/1b -/-mice compared to WT mice (p < 0.001) (Fig. 7C) 
Discussion
In this study, we conducted a systematic evaluation to define relevant OATP transporters involved in doxorubicin uptake and clearance. We identified multiple OATPs, including human OATP1A2, OATP1B1 and OATP1B3, capable of transporting doxorubicin in vitro. Rat Oatp1a1 and Oatp1a4 were also associated with doxorubicin transport in vitro. Since OATP1B1 and OATP1B3 are expressed primarily at the basolateral membrane of hepatocytes (Abe et al., 2001; Konig et al., 2000a; , these results suggest potential important roles for these transporters in the hepatic uptake and clearance of doxorubicin. In mice, absence of Oatp1a/1b transporters led to a substantial increase in the plasma exposure and a corresponding decrease in the hepatic uptake and clearance of doxorubicin. Accordingly, we demonstrate that OATP1A/1B transporters play significant roles in the disposition of doxorubicin.
Our initial studies revealed doxorubicin to be an efficient substrate for human OATP1A2, but not OATP1B1 and OATP1B3, when assessed in detail using a recombinant vaccinia-based method in a HeLa cell system. However, for reasons that are not well-defined, OATP-mediated uptake of certain substrates, including drugs such as doxorubicin and docetaxel, has been noted by other groups to be variably discrepant in results amongst in vitro systems or when comparing This article has not been copyedited and formatted. The final version may differ from this version. in vitro to in vivo transport (de Graan et al., 2012; Durmus et al., 2014; Lee et al., 2015; . Hence, absence of doxorubicin transport in HeLa cells does not preclude it to be transported in vitro by OATP1B transporters in another system. Thus, another goal of this study was to establish an in vitro cell model system to explore OATP-mediated transcellular transport of substrate drugs and the interplay with MDR1, an efflux transporter that is known to transport doxorubicin. In this manner, establishing directional doxorubicin transport evaluating the interplay between uptake and efflux may better recapitulate drug transport that occurs in vivo.
Recently, we generated and characterized MDCKII cells stably expressing OATP1B and/or MDR1 transporters . Similarly, we created a model cell system stably expressing OATP1A2 in MDCKII monolayers and used this to examine the effect of OATP1A2 expression and the interplay with MDR1 on transcellular transport of doxorubicin.
The membrane localization of OATP1A2 and MDR1 expressed transiently in MDCKII cells transduced by BacMam virus was previously confirmed by confocal imaging (Liu et al., 2015) . Likewise, in our study, we assessed membrane expression of OATP1A2 and MDR1 in doxorubicin counteracts OATP1A2-mediated uptake. To the best of our knowledge, this is the first report using polarized MDCKII cells transfected stably by OATP1A2 and MDR1 cDNA constructs for drug transport. Collectively, our data indicates doxorubicin is a good substrate for OATP1A2 which is in agreement with a previous report demonstrating OATP1A2-mediated doxorubicin transport in HEK293 cells (Durmus et al., 2014) .
Mice deficient in Oatp1a/1b transporters have been generated and functionally characterized for in vivo transport of endogenous or xenobiotic OATP substrates (van de Steeg et al., 2010; Zaher et al., 2008) . Durmus et al. demonstrated that doxorubicin disposition was affected by mouse and human OATP1A/1B transporters using Slco1a/1b2 -/-mice and humanized transgenic mice (Durmus et al., 2014) . Slco1a/1b2 -/-mice demonstrated significantly higher plasma concentrations and AUC than wild-type mice. Interestingly, liver-specific expression of OATP1A2 in Slco1a/1b2 -/-mice could restore plasma levels of doxorubicin to those of wild-type mice. However, OATP1A2 is not natively expressed in human liver other than cholangiocytes (Lee et al., 2005) . We performed similar doxorubicin distribution experiments in Slco1a/1b2
-/-and wild-type mice. We did not witness significant differences in doxorubicin concentrations in kidneys or the brains of Slco1a/1b2 -/-mice compared to their wild-type counterparts, where OATP1A2 is physiologically expressed. This could be related, in part, due to effects of native Mdr1a/1b-mediated doxorubicin efflux in these tissues counteracting Oatp1a-mediated uptake.
We also can not rule out that doxorubicin may be a substrate for other transporters expressed in these tissues that may modulate tissue-specific uptake and transport.
We and others previously reported that OATP1A2 was overexpressed in breast cancer normal breast tissue. OATP1A2 is known to transport endogenous substrates such as the estrogen metabolites estrone sulfate and estradiol glucuronide, which in turn may promote cellular proliferation (Nozawa et al., 2004; Nozawa et al., 2005) . Notably, one of the major active chemotherapeutic agents used in breast cancer treatment is doxorubicin (Nagar, 2010) .
Thus, it is plausible that its efficacy in breast cancer treatment could be related to the fact that doxorubicin is an excellent OATP1A2 substrate and hence would preferentially accumulate in breast cancer cells due to OATP1A2 overexpression. Indeed, a recent study in breast cancer patients indicated those tumors with high expression of OATP1A2 was an independent predictor of good pathologic response to anthracycline and taxane-based chemotherapy (Hashimoto et al., 2014) . This merits further investigation as this data would suggest that OATPs may be an appropriate drug target when overexpressed in tumor tissues as chemotherapeutic agents which are good OATP substrates would preferentially accumulate in tumor cells which may enhance therapeutic efficacy.
We did not initially identify doxorubicin as a substrate for OATP1B1 or OATP1B3 when transiently overexpressed in HeLa cells. However, it has been previously documented that ~50% of doxorubicin's disposition is mediated by biliary elimination, suggesting hepatic uptake and clearance play important roles in its disposition (Danesi et al., 2002) . We further evaluated the vectorial transport of doxorubicin in transwells using polarized MDCKII cell lines stably OATP1B3 mediate hepatic uptake of doxorubicin and MDR1 mediates hepatic efflux. In addition to OATP1A2 overexpression in breast cancer tissues and cell lines as previously noted, OATP1B1 has also been noted to be expressed in cancer tissues, including colon cancer, ovarian cancer, hepatocellular carcinoma, while OATP1B3 has been shown to be expressed in gastric cancer, colon cancer, and pancreatic cancers (Thakkar et al., 2015) . Of course, MDR1 has long been known to be overexpressed in a number of cancers, leading to the multidrug resistance phenomenon by which many tumors develop chemotherapy resistance (Fojo et al., 1987 doxorubicin (Okabe et al., 2005) , and is expressed in testis, fetal liver, bone marrow, peripheral blood leukocytes, leukemias and some cancer cell lines, but not in liver or kidney (Gong et al., 2002 (Durmus et al., 2014) . Collectively, our results confirm that OATP1B/1b transporters are important to the hepatic uptake and clearance of doxorubicin. Of note, the differential expression of OATPs in tissues of importance to drug disposition may also contribute to doxorubicin-mediated adverse effects. For instance, as OATP1B1 and OATP1B3
are highly expressed in the liver, the recommendation that doxorubicin dose be reduced in patients with hepatic impairment would suggest the important roles these transporters play in the clearance of doxorubicin.
Significant genetic variability in OATP transporters exists and contributes to variation in drug disposition (Gong and Kim, 2013) . Population pharmacokinetic studies demonstrate significant interindividual differences in doxorubicin disposition with up to 30% differences in doxorubicin clearance in oncology patients (Kontny et al., 2013) . We evaluated the effect of SLCO1A2 polymorphisms on doxorubicin transport in vitro in HeLa cells. Lee et al. previously identified 6 nonsynonymous SNPs in exonic regions of SLCO1A2 gene from an ethnically diverse population and functionally characterized the associated variant proteins in vitro (Lee et al., 2005) . When we examined these 6 polymorphisms for doxorubicin transport, four variants, including 38T>C, 404A>T, 516A>C, and 559G>A, led to significantly decreased uptake of doxorubicin in vitro. was even unaffected by rosuvastatin (Eechoute et al., 2011) . Another study indicated that lopinavir was transported by OATP1A2 in Xenopus laevis oocytes, but the association between SLCO1A2 polymorphisms, 38T>C and 516T>G, and plasma concentrations of lopinavir in cancer patients was not observed (Hartkoorn et al., 2010) . Therefore, the relevance of OATP1A2 variants to doxorubicin disposition in vivo warrants further investigation.
In conclusion, we describe important roles for OATPs, including OATP1A2, OATP1B1 This article has not been copyedited and formatted. The final version may differ from this version. concentration in liver (B) and the liver-to-plasma ratio (C) were significantly lower in Slco1a/1b-/-mice compared to wild-type mice. Data were expressed as mean ± SD (n = 8 for WT mice; n = 6 for KO mice; 8-13 weeks of age). *, p<0.05; **, p<0.01; ***, p<0.001.
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